Study Design This is an unpowered pilot study to determine the sensitivity of the new SmartGoggles device, for detection of ICG fluorescence in SLNs of breast cancers in a clinical setting. The investigators have chosen to examine ICG as the contrast agent and breast cancer as the clinical target, because this agent is FDA-approved and is regularly used for lymphatic mapping (skin cancers). The study team will be applying ICG for the same length of time as the standard-of-care procedures including radiotracers and blue dyes. The study involves a single visit, lasting ~3-4 hours total. Multiple biopsies will be performed if multiple SLNs are identified. The study will enroll 6 patients, and then be suspended for an interim analysis. If it is determined that more data are needed to reliably determine the endpoints, then 4 additional patients will be recruited, for a total of 10 patents.